Abstract
CD38 is a multifunctional enzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. Recently, CD38 was also identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. Due to the emerging role of NAD as a key molecule in multiple signaling pathways, and metabolic conditions it is imperative to determine the cellular mechanisms that regulate the synthesis and degradation of this nucleotide. In fact, recently it has been shown that NAD participates in multiple physiological processes such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity. The discovery of CD38 as the main cellular NADase in mammalian tissues, and the characterization of its role on the control of cellular NAD levels indicate that CD38 may serve as a pharmacological target for multiple conditions.
Keywords: CD38, NAD, SIRT1, aging, obesity, metabolic syndrome
Current Pharmaceutical Design
Title: CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Volume: 15 Issue: 1
Author(s): Eduardo Nunes Chini
Affiliation:
Keywords: CD38, NAD, SIRT1, aging, obesity, metabolic syndrome
Abstract: CD38 is a multifunctional enzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. Recently, CD38 was also identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. Due to the emerging role of NAD as a key molecule in multiple signaling pathways, and metabolic conditions it is imperative to determine the cellular mechanisms that regulate the synthesis and degradation of this nucleotide. In fact, recently it has been shown that NAD participates in multiple physiological processes such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity. The discovery of CD38 as the main cellular NADase in mammalian tissues, and the characterization of its role on the control of cellular NAD levels indicate that CD38 may serve as a pharmacological target for multiple conditions.
Export Options
About this article
Cite this article as:
Chini Nunes Eduardo, CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185788
DOI https://dx.doi.org/10.2174/138161209787185788 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Adiponectin in Asthma: Implications for Phenotyping
Current Protein & Peptide Science Meet Our Editor
Current Metabolomics Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Non-Peptidic Inhibitors of Cysteine Proteases
Mini-Reviews in Medicinal Chemistry Atopy and Role of Mast Cells in IgE-Mediated Allergic Diseases
Current Immunology Reviews (Discontinued) Developmental Current and Future Therapy for Severe Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery
Current Pharmaceutical Design Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Preparation and Evaluation of ‘3 Cap’ Pulsatile Drug Delivery System of Ramipril
Cardiovascular & Hematological Agents in Medicinal Chemistry The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution
Current Molecular Pharmacology Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates
Current Topics in Medicinal Chemistry Asthma COPD Overlap Syndrome: An Approach to A Real -World Endotype in Obstructive Lung Disease?
Current Pharmaceutical Design Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Chronic Obstructive Pulmonary Disease and Oxidative Stress
Current Pharmaceutical Biotechnology Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy